Entering text into the input field will update the search result below

AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack

Nov. 09, 2022 1:45 AM ETAbCellera Biologics Inc. (ABCL)LLY, REGN61 Comments
Confoundedinterest profile picture


  • AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines.
  • The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform.
  • The company's proprietary suite of T-cell engagers, billed as the world's largest and the internal GCPR effort, continues to develop and may offer compelling partnership opportunities in the near future.
  • The company's currently marketed COVID antibody is unlikely to be useful against new, emerging variants, however, the company announced yet another bullet in the chamber.
  • The company is flush with cash and is fully funded for the completion of its CNC/GMP facility expected in 2024, which will provide meaningful acceleration and revenue potential to partnered programs.

Female Research Scientist with Bioengineer Working on a Personal Computer with Screen Showing Virus Analysis Software User Interface. Scientists Developing Vaccine, Drugs and Antibiotics in Laboratory


Many long-time followers of mine are familiar with my rather outsized long position in AbCellera Biologics (ABCL). Currently, it makes up a whopping 46% of my speculative portfolio; and as such, when they report, I tend to pay very

Molecules in the clinic




Internal Programs




This article was written by

Confoundedinterest profile picture
I work in the financial and property management industry for a well known, publicly traded "mini Berkshire" Insurance company. I focus on portfolio structure, value, reasonably priced growth, tech and biotech spaces. I passed the series 6 and 7 exams at age 18 but do not at this time have active licenses.My passion for investing and personal finance education began at a very early age. I opened my first brokerage account at the age of 12 and have invested through crashes, crises, recessions and bubbles. I have made many mistakes in both my personal and investing lives, however, each mistake I have made has taught me valuable lessons on my journey, both in life and towards financial independence. As of March 2023, my total portfolio has compounded at 10.2% per year since 1993, beating the S&P 500's return of 9.87% over the same time period. I do not currently hold active licenses and I am not a financial advisor and do not give out or publish investment advice. Articles I write are my opinion only and are not solicitations, please seek guidance from a licensed financial advisor before investing in any security. Opinions expressed in my articles are my own and do not reflect or indicate any positions or opinions held of my primary employer.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am not a licensed financial advisor. This is not a solicitation to buy or sell a specific security nor is it to be construed as investment advice, please contact your licensed financial and tax advisor for advice on your specific situation. This article is an opinion piece only and should not be construed as fact or be represented as such, please perform your own due diligence prior to investing in this or any equity.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.